Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocyte disarray and fibrosis.
• Current management focuses on symptom relief and preventing sudden cardiac death.
• Disease-modifying options were limited to septal reduction therapy or heart transplantation.

Purpose of the Study:

• To review the emerging evidence on cardiac myosin inhibitors as a novel pharmacotherapy for HCM.
• To examine the effects of cardiac myosin inhibitors and surgical myectomy on cardiac remodeling.
• To assess the potential for these interventions to modify the disease course in HCM.

Main Methods:

• Review of existing clinical studies and evidence on cardiac myosin inhibitors in HCM.
• Analysis of data on surgical myectomy outcomes in hypertrophic obstructive cardiomyopathy.
• Evaluation of cardiac imaging and functional parameters to assess reverse remodeling.

Main Results:

• Cardiac myosin inhibitors and surgical myectomy provide symptomatic benefits and reduce left ventricular outflow tract obstruction.
• Both interventions demonstrate favorable reverse remodeling, including reduced left ventricular mass and improved diastolic function.
• Observed improvements include decreased left atrial volumes and enhanced left atrial strain.

Conclusions:

• Cardiac myosin inhibitors represent a promising novel pharmacotherapy for hypertrophic cardiomyopathy.
• Surgical myectomy and cardiac myosin inhibitors induce significant positive cardiac remodeling.
• Further research is needed to establish long-term durability and clinical significance of these findings.